Gene therapy for cancer through adenovirus vector-mediated expression of the Ad5 early region gene 1A based on loss of IGF2 imprinting

Oncology Reports

Volumn 30, Issue 4, 2013, Pages 1814-1822

  Pan, Yuqin ^a   He, Bangshun ^a   Lirong, Zhang ^a   Nie, Zhenlin ^a   Chen, Liping ^a,b   Gu, Ling ^a,b   Hoffman, Andrew R ^c,d   Wang, Shukui ^a   Hu, Jifan ^c,d  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING NORMAL UNIVERSITY   (China)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

Adenoviral vector; CTCF; Gene therapy; Genomic imprinting; Insulin like growth factor 2 gene

Indexed keywords

ADENOVIRUS VECTOR; E1A PROTEIN; ENHANCED GREEN FLUORESCENT PROTEIN; MESSENGER RNA; SOMATOMEDIN B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER GROWTH; CANCER INHIBITION; CELL STRAIN HRT 18; CELL STRAIN HT29; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; E1A GENE; GENOME IMPRINTING; HUMAN; HUMAN CELL; IGF2 GENE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; DNA METHYLATION; GENETIC THERAPY; GENETIC VECTORS; GENOMIC IMPRINTING; GREEN FLUORESCENT PROTEINS; HCT116 CELLS; HETEROGRAFTS; HT29 CELLS; HUMANS; INSULIN-LIKE GROWTH FACTOR II; MCF-7 CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROMOTER REGIONS, GENETIC; RNA, LONG NONCODING; RNA, MESSENGER;

EID: 84882578291     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2646     Document Type: Article

References (26)

1. Rainier S, Johnson LA, Dobry CJ, Ping AJ, Grundy PE and Feinberg AP: Relaxation of imprinted genes in human cancer. Nature 362: 747-749, 1993.
2. Feinberg AP: Genomic imprinting and gene activation in cancer. Nat Genet 4: 110-113, 1993.
3. Reik W, Constancia M, Dean W, Davies K, Bowden L, Murrell A, Feil R, Walter J and Kelsey G: Igf2 imprinting in development and disease. Int J Dev Biol 4: 145-150, 2000.
4. Arney KL: H19 and Igf2-enhancing the confusion? Trends Genet 19: 17-23, 2003.
5. Thorvaldsen JL, Duran KL and Bartolomei MS: Deletion of the H19 differentially methylated domain results in loss of imprinted expression of H19 and Igf2. Genes Dev 12: 3693-3702, 1998.
6. Hark AT, Schoenherr CJ, Katz DJ, Ingram RS, Levorse JM and Tilghman SM: CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature 405: 486-489, 2000.
7. Bell AC and Felsenfeld G: Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. Nature 405: 482-485, 2000.
8. Kanduri C, Pant V, Loukinov D, et al: Functional association of CTCF with the insulator upstream of the H19 gene is parent of origin-specific and methylation-sensitive. Curr Biol 10: 853-856, 2000.
9. Ling JQ, Li T, Hu JF, et al: CTCF mediates interchromosomal colocalization between Igf2/H19 and Wsb1/Nf1. Science 312: 269-272, 2006.
10. Leighton PA, Saam JR, Ingram RS, Stewart CL and Tilghman SM: An enhancer deletion affects both H19 and Igf2 expression. Genes Dev 9: 2079-2089, 1995.
11. Schoenherr CJ, Levorse JM and Tilghman SM: CTCF maintains differential methylation at the Igf2/H19 locus. Nat Genet 33: 66-69, 2003.
12. Fedoriw AM, Stein P, Svoboda P, Schultz RM and Bartolomei MS: Transgenic RNAi reveals essential function for CTCF in H19 gene imprinting. Science 303: 238-240, 2004.
13. Chen HL, Li T, Qiu XW, et al: Correction of aberrant imprinting of IGF2 in human tumors by nuclear transfer-induced epigenetic reprogramming. EMBO J 25: 5329-5338, 2006.
14. Vile RG, Russell SJ and Lemoine NR: Cancer gene therapy: hard lessons and new courses. Gene Ther 7: 2-8, 2000.
15. Gómez-Navarro J, Curiel DT and Douglas JT: Gene therapy for cancer. Eur J Cancer 35: 2039-2057, 1999.
16. Robbins PD and Ghivizzani SC: Viral vectors for gene therapy. Pharmacol Ther 80: 35-47, 1998.
17. Branton PE, Bayley ST and Graham FL: Transformation by human adenoviruses. Biochim Biophys Acta 780: 67-94, 1985.
18. Radke JR, Siddiqui ZK, Miura TA, Routes JM and Cook JL: E1A oncogene enhancement of caspase-2-mediated mitochondrial injury sensitizes cells to macrophage nitric oxide-induced apoptosis. J Immunol 180: 8272-8279, 2008.
19. Sánchez-Prieto R, Quintanilla M, Cano A, et al: Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1A gene. Oncogene 13: 1083-1092, 1996.
20. Adler V, Yin Z, Fuchs SY, et al: Regulation of JNK signaling by GSTp. EMBO J 18: 1321-1334, 1999.
21. Szabó PE and Mann JR: Biallelic expression of imprinted genes in the mouse germ line: implications for erasure, establishment, and mechanisms of genomic imprinting. Genes Dev 9: 1857-1868, 1995.
22. Kaneda A and Feinberg AP: Loss of imprinting of IGF2: a common epigenetic modifier of intestinal tumor risk. Cancer Res 65: 11236-11240, 2005.
23. Li T, Hu JF, Qiu X, et al: CTCF regulates allelic expression of Igf2 by orchestrating a promoter-polycomb repressive complex 2 intrachromosomal loop. Mol Cell Biol 28: 6473-6482, 2008.
24. Hu JF, Vu TH and Hoffman AR: Promoter-specific modulation of insulin-like growth factor II genomic imprinting by inhibitors of DNA methylation. J Biol Chem 271: 18253-18262, 1996.
25. Kurukuti S, Tiwari VK, Tavoosidana G, et al: CTCF binding at the H19 imprinting control region mediates maternally inherited higher-order chromatin conformation to restrict enhancer access to Igf2. Proc Natl Acad Sci USA 103: 10684-10689, 2006.
26. Yoon YS, Jeong S, Rong Q, Park KY, Chung JH and Pfeifer K: Analysis of the H19ICR insulator. Mol Cell Biol 27: 3499-3510, 2007.